(C) GMA News
Last updated on May 18th, 2021 at 05:27 am
Abu Dhabi – Hundreds of Filipinos were included among the thousands who volunteered in the Phase III of COVID-19 vaccine trials in the United Arab Emirates.
According the the statement released by the Department of Foreign Affairs, that Group 42 (G42), the bu Dhabi-based technology company, is currently on its human (phase III) trials for the vaccine.
The vaccine in development is also in collaboration by Chinese company Sinopharm at the Abu Dhabi National Exhibition Centre (ADNEC).
Philippine Ambassador to the UAE Hjayceelyn Quintana said that hundreds of Filipino nurses and volunteers took part on the potential COVID-19 vaccine trials.
She visited the Abu Dhabi National Exhibition Centre (ADNEC) and Group 42 Chief Research Officer Dr. Waleed Zaher gave her an overview on the trial process.
The ADNEC trial site, regarded as the biggest trial site in the world, was able to administer the trial vaccine to over 15,000 people with nationalities.
Around 180 Filipino nurses and 1 doctor were involved in the COVID-19 vaccine trials. The United Arab Emirates is one of the first countries to ever conduct Phase III trial for the potential COVID vaccine that is in development by the Chinese pharmaceutical firm, Sinopharm.
Many fans and industry professionals saw Prithviraj Sukumaran's L2 Empuraan movie release on Thursday as a mixed success that gained…
Filipina teenager Alexandra Eala, 19 year old girl has achieved one of the biggest milestones in WTA season by defeating…
After waiting for a solid six years, Marvel Studios has divulged its next Avengers movie—Avengers: Doomsday. And the cast is…
Through software update Nothing OS 3.1 the company improves functionality of Phone (3a) and Phone (3a) Pro models. Global service…
China's electric vehicle (EV) giant BYD has officially taken over the global EV market, with a whopping revenue of 777…
The Japanese women’s curling team has a tough road to qualification for the 2026 Milan-Cortina Winter Olympics. Having silver and…
This website uses cookies.
Read More